Eagle Pharmaceut Stock Price, News & Analysis

Eagle Pharmaceuticals (Nasdaq: EGRX) announced a licensing agreement with AOP Orphan Pharmaceuticals for the U.S. rights to Landiolol, an ultra-selective beta-1 blocker approved in Europe for tachycardia. Eagle will submit a new drug application (NDA) to the FDA for Landiolol's approval for short-term ventricular rate reduction in supraventricular tachycardia (SVT). The agreement includes a $5 million upfront payment and potential future payments upon regulatory approvals. Landiolol shows promise for critical care management and has the potential for pediatric applications.

Eagle Pharmaceuticals (Nasdaq: EGRX) announced the release of its Q2 2021 financial results on August 9, 2021, prior to market opening. CEO Scott Tarriff and CFO Brian Cahill will lead a conference call at 8:30 a.m. ET to discuss the results. Participation details include toll-free numbers for U.S. and international callers and a webcast available for replay. The company focuses on innovative medicines with products like RYANODEX®, BENDEKA®, and BELRAPZO®. Additional information is available on their website.

Eagle Pharmaceuticals (Nasdaq: EGRX) announced the FDA has maintained Priority Review for its ANDA for vasopressin, with a GDUFA date set for December 15, 2021. The response to the CRL was submitted on June 15, 2021. CEO Scott Tarriff emphasized the importance of this program, highlighting its COVID priority status, and expressed confidence in a commercial launch before the year ends. Eagle is the first to file an ANDA for vasopressin, which had U.S. sales of $786 million in 2020.

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) announced it has responded to the Complete Response Letter (CRL) concerning its Abbreviated New Drug Application (ANDA) for vasopressin. The company believes it has fully addressed the FDA's concerns and expects final approval soon, highlighting the product as a critical program with significant potential value for shareholders. Eagle is the first to file an ANDA referencing Vasostrict, which earned $786 million in U.S. sales in 2020. The company prioritizes this application as a COVID-related project, aiming for a launch within the year.

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) announced that CEO Scott Tarriff and CFO Brian Cahill will present at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 1:30 p.m. Eastern Time. The presentation will be available for live webcast and archived for 30 days on Eagle's website. Eagle is a fully integrated pharmaceutical company focusing on innovative medicines that significantly improve patient outcomes, with products like RYANODEX®, BENDEKA®, and BELRAPZO®. More details can be found at www.eagleus.com.

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) will present at the 2021 RBC Capital Markets Global Healthcare Conference on May 18, 2021, at 1:20 p.m. Eastern Time. CEO Scott Tarriff and CFO Brian Cahill will lead the presentation, which will be available via a live webcast and archived for 30 days on the company’s website under the Investors Section. Eagle is dedicated to developing innovative medicines, with commercialized products including RYANODEX®, BENDEKA®, and BELRAPZO®. For more information, visit www.eagleus.com.

Eagle Pharmaceuticals announced its Q1 2021 financial results, reporting total revenues of $41.2 million, down from $46.0 million in Q1 2020, attributed to decreased sales of RYANODEX and lower royalties from BENDEKA. The net loss narrowed to $0.4 million, compared to $2.9 million a year prior. Significant business highlights include FDA study completion for vasopressin, TREAKISYM approval in Japan, and active discussions for new in-licensing opportunities. Eagle anticipates $20-$25 million from TREAKISYM in 2022.

Eagle Pharmaceuticals announced the filing of TREAKISYM RI (50ml) with Japan's Pharmaceuticals and Medical Devices Agency (PMDA). This application is based on clinical studies confirming the safety and pharmacokinetics of the 10-minute intravenous infusion. CEO Scott Tarriff expressed optimism about reaching peak income of $20-$25 million next year from TREAKISYM products. The RI formulation notably reduces infusion time from 60 to 10 minutes, enhancing patient and healthcare provider experience. Eagle's partnership with SymBio supports the commercialization of these products in Japan.

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) has appointed Dr. Luciana Borio to its Board of Directors. Dr. Borio's extensive experience includes significant roles at the FDA and the National Security Council, focusing on public health and infectious diseases. Eagle's CEO Scott Tarriff expressed optimism about her contributions to the company's growth and advancement of its product pipeline. Dr. Borio's background includes leadership in biodefense policy and medical countermeasures, which aligns with Eagle's strategic goals. This appointment reflects Eagle's commitment to enhancing its expertise in addressing unmet medical needs.